Immunotoxicology
Specialty Section NewsletterPre si de nt ’s M es s ag e
Steve Pruett2007 - 2008
Executive Committee
President
Dr. Stephen B. Pruett
Vice President
Dr. Jeanine L. B ussiere
Vice President-Elect
Dr. Jean Regal
Secretary-Treasurer
Dr. Helen V . Ratajczak
Past President
Dr. Mitchell D . Cohen
Senior C ouncilor
Dr. Rodney R. Dietert
Junior Councilor
Dr. Danuta Herzyk

As indicated in the report from the Program Committee in this Newsletter,
Jeanine and the Committee were successful in recruiting and selecting a number of excellent proposals that have now been favorably received by the SOTProgram Committee. As a result, the program at 2008 SOT Meeting promises
to be very enjoyable and informative for immunotoxicologists. As usual, there
will be something for everyone, from applied to basic and back again.
As an academician, I have enjoyed observing the interactions between colleagues in this specialty section who work for regulatory agencies or industry.
I wish the public could see what I have seen. My distinct impression is that all
parties are genuinely interested in doing the research appropriately and using
the data wisely to best serve human and environmental health.
An ad hoc committee has been formed to address the problems related to the
new structure of Study Sections at NIH. The situation has not improved, andPat Mastin (NIEHS) provided results indicating that the success rate for funding of immunotoxicology projects has been dismal. We are now trying to arrange a conference call with the SOT Task Force working on this issue. We
plan to offer any assistance we can to help the Task Force in this importanttask. Please contact me if you have any ideas, specific concerns, or examples
of problems that might help this committee.

Post-Doc Repr esentative
Dr. Stacey Anderson
Student R epresentative
Sheung Ng
The Immunotoxicology Specialty Section Newsletteris published 3 times/year (May, August and November). If you would like to share a book review, meeting report, interesting web site or any other item ofinterest with members of the Specialty Section,please send it to us by the middle of the month
preceding the planned publication date. All comments on, or suggestions for, the newsletter are
welcome.
Helen V. Ratajczak, Ph.D., Editor
94C Miry Brook Road
Danbury, CT 06810
Tel. (203) 778-6826 Fax (203) 748-6512
hratajcz@comcast.net
Stephen B. Pruett, Ph.D., Associate Editor
Professor and Head
College of Veterinary Medicine
Dept of Basic Sciences
Mail Stop 9825
Mississippi State University
Mississippi State, MS 39762
Tel. [(662) 325-8884 Fax (662) 325-1031
Pruett@cvm.msstate.edu
Typesetting provided by L. Peyton Myers, Ph.D.

August 2007

A group from our Specialty Section has begun planning a Current Concepts in
Toxicology Conference. These conferences are designed to bring scientists
together to consider a single issue in a manner that is more thorough andthoughtful than is possible at the Annual Meeting of SOT. I mention this justto remind you that these Conferences can be very useful, and I would encourage you to consider proposing one. Please be aware, however, that the minimum lead-time is at least 6 months, so begin preparing early. The Specialty
Sections are responsible for financing these events, and the goal is to makethem revenue neutral (registration fees are sufficient to cover the costs). However, SOT will step in if there are unanticipated losses that cannot be coveredby the Specialty Section’s budget. Please contact me if you are interested inproposing a CCT.
\\\

Committee reports ........................................................ page 2
Financial report ............................................................ page 7

1

Immunotoxicology Specialty Section

Finally, I would like to give you
updates on two issues that Dr.
Cohen emphasized during his
Presidency. First, we have notabandoned the idea of seeking
contributions from companies topermit the Specialty Section to doeven more for students travelingto meetings or to learn new techniques in another lab. However,
the recent emphasis by SOT on
supporting the SOT Foundation
has muddied the waters with regard to whether we will be able todo this. If SOT will permit it, I do
plan to pursue it. Second, Mitch
did a great deal to encourage interactions between the immunotoxicologists in Japan andEurope with those in the US.
I am pleased to announce two new
initiatives to keep the momentum
going. The Specialty Section Executive Committee voted to provide airfare for a non-US resident
post-doc to attend the annual SOT
meeting. Graduate students canalready apply for student travel
awards, but assistance for postdoc travel would be unique. Look
for an announcement in the next
newsletter or in a special e-mailregarding the criteria and application procedure for this travel
award. The Awards Committee
will be developing these soon.
Also, the Executive Committee
voted to support the travel expenses of a Japanese colleague toattend the SOT meeting this year
and speak at our business meetingfor about 10 minutes on“Immunotoxicology in Japan”.
For now, this is a one time event;
we hope to continue the exchanges in the future.

August 2007

Student andPost-doctoral
ReportSubmitted by Stacey Anderson,
Post-doctoral Representative, andSheung Ng, Student Representative
Greetings fellow students andpost-docs! Not too much haschanged since the last newsletterso I just want to remind/update
you on a few things. Please continue to watch for information
about our meeting place in upcoming communications from theISS as the national meeting approaches.
I’m still searching for a meeting
place for the mixer in Seattle, so if
anyone is familiar with the areaand has suggestions or recommendations for where the mixer could,
be please let me know. Also, anyother thoughts on how to increase
student/post-doc participation at
the mixers would be appreciated.
We hope more of you attend future mixers: it is a great way to get
to know the other students/postdocs in ISS.
For those of you looking for themost up-to-date information related to SOT, please visit the SOT
website for students and postdocs: http://www.toxicology.org/
index.asp?navTop=3

students and post-docs. Links arealso available for career resourcesand development services as well
as awards and fellowships. Postdoctoral members can also findgreat resources for scientificgrowth, networking, and careeradvancement from the PostDoctoral Assembly (PDA).
Check out the online version of
the PDA semi-annual newsletter
for more information:
http://
ww w. t o xico lo g y. o r g / a i/ s pd/
SOTPDAnewsletterspring2007.pdf
Similar information is available
for graduate students through theStudent Advisory Council (SAC).
The SAC aims at addressing theneeds of students in the Society
and encourages student participation and membership. Please visit
the SAC website for more inform a t i o n :h t t p : / /ww w. t o xico lo g y. o r g / a i/ s pd/
studentservices.asp#SAC
We are still looking for the next
student representative of the ISS.
Sheung Ng’s term runs out next
year and we are looking for her
replacement. All your advisor has
to do is send a letter of recommendation to the ISS president that
includes verification that he or she
can fund your travel to SOT forthe next two years. Your term
would run from March 2008March 2010 and you would serveas the student voice on the ISS.

This useful website provides information such as online versionsof SOT newsletters, highlights ofpast meetings, SOT forums forinteractive discussion and resources for undergrads, graduate

If you have any questions about
student representation in the ISSor how the ISS can best serve you
as a student of immunotox, please
do not hesitate to contact me atsanderson4@cdc.gov or Sheung at
ng@env.med.nyu.edu.

2

Immunotoxicology Specialty Section

Program Com-

Program Committee andhave them help you flush out
your idea and turn it into a
program proposal.

mittee Update
Submitted by Jean Regal
I know it seems early because we arejust half way through 2007 and theprogram for 2008 has barely been
settled. However, we already need
to begin working on the Immunotoxicology Specialty Section program proposals for the Baltimore
SOT meeting in 2009!
Deadline for proposal submission:
November 30, 2007.
Step 1: Think about the Symposium,
Workshop, Roundtable orContinu ing Education
Course that you always
wanted to attend.
Step 2: Sketch out a possible title
and/or speakers
Step 3: Contact any member of theStep 4: Submit your proposal to
jr e ga l@ d.u mn. e du b y
November 30, 2007
The Immunotoxicology Specialty
Section has traditionally sponsored
excellent and well-attended programs at the Annual Meeting. The
Program Committee comes up withmany good ideas year after year, but
depends on ALL of the members of
the Immunotoxicology Specialty
Section to generate ideas for outstanding proposals.
Helpful information

proposing Continuing Education
Courses, Symposia, Workshop, andRoundtables Information are available on the SOT website underForms and Applications – On Line
Proposals for Annual Meeting Sessions. (http://www.toxicology.org/ai/
fa/formsapps.asp)
Symposia
Cutting-edge science, new areas for
toxicologists, new concepts or approaches, new data♦

165 minutes or less♦

Chairperson and 3-4 speakers(~30-35 minutes per speaker)♦

Summary of symposium by last
speakerWorkshop

Past Immunotoxicology programs
are now listed on our website (http://w w w. t ox ic o l og y. or g/ I S OT /S S/
immunotox/Index.html)

Emphasis on quality presentation ofgenerally accepted, state-of-the-art
knowledge in toxicology♦

165 minutes or less

Sample proposals and guidelines for♦

Chairperson and 1-5 speakers

2007-2008
Program Committee
Jean Regal (Chair) jregal@d.umn.edu

Lin Mantell

mantelll@stjohns.edu

Tony Arulanandam tonyarul@comcast.net

Prakash Nagarkatti

pnagark@med.sc.edu

Sarah Blossom

BlossomSarah@uams.edu

Keiko Nohara

keikon@nies.go.jp

Jeanine Bussiere(mandated)bussierj@amgen.com

Marc Pallardy

Marc.pallardy@u-psud.fr

Nikolay Filipov

filipov@cvm.msstate.edu

Steve Pruett (mandated)

Pruett@cvm.msstate.edu

Deborah FincoKent

Deborah.fincokent@pfizer.com

Lisa Ryan

Ryan/k@uams.edu

Barb Kaplan

blKaplan@msu.edu

Jennifer Schlezinger

jschlezi@bu.edu

Ian Kimber

ian.kimber@syngenta.com

MaryJane Selgrade

Selgrade.maryjane@EPA.gov

Raj Krishnaraj

rkrishna@ulc.edu

Lewis Shi

shil@svm.vetmed.wisc.edu

David Lawrence

lawrencd@wadsworth.org

Mike Woolhiser

mwoolhiser@dow.com

Lynne LeSauteur

lynne.lesauteur@ca.crl.com

Courtney Sulentic(CE Committee)

courtney.sulentic@wright.edu

August 2007

3

Immunotoxicology Specialty Section

♦

Informal, interactive presentations♦

Emphasis on discussion

Roundtable
Controversial subject matter♦

80 minutes or less♦

Chairperson(s) and 2-4 speakers♦

Each speaker makes a 5-10
minute statement (Moderator
coordinates the comment)♦

Comments coordinated by chairperson♦

Balance of time for questions
and discussionof the responding groups included
the Immunotoxicology TechnicalCommittee (ILSI-HESI) and BioSafe. Some of the recommendations
submitted included:•

The use of a risk-based assessment strategy for decisions related to immunogenicity assessment (similar to US regulators’
strategies already in place)•

Clarification of scope to apply tothe nonclinical and clinical assessment of immunogenicity as
defined by the detection of antidrug antibodies (This applies toproteins and polypeptides, aswell as their derivatives andproducts of which they are components.)

Continuing Education Courses♦♦♦

Emphasis on quality presentation of generally accepted, stateof-the-art knowledge in toxicology•

Organization of nonclinical andclinical requirements in separate
sections•

Additional information regarding the evaluation of neutralizing antibodies and the application of this data to both nonclinical and clinical studies•

Evaluation of cellular immune
responses on a case by casebases, in addition to the standard
evaluation of the humoral response•

Assurance of consistency with
the Immunogenicity section of
ICH S6 Preclinical Safety
Evaluation of Biotechnology Deri ved Pha rma ceuti ca ls(Address those recommendations that differ.)

CE Courses:♦

240 minutes or less♦

Chairperson(s) and 3-4
speakers (syllabus andslide presentation)

Sunrise Mini-Course♦

60 minutes♦

1 speaker (syllabus andslide presentation)

Regulatory
Committee
UpdateSubmitted by Wendy Komocsar
The response period has ended (31Jul-2007) for the EMEA draft guidance on the Immunogenicity Assessment of Biotechnology-Derived
Therapeutic Proteins, (EMEA/
CHMP/BMWP/14327/2006). Two

August 2007

Pharma, Regulatory and Academic
colleagues gathered in Washington,
D.C. in the middle of May for aworkshop on the Development of
Immunomodulatory Agents. The
workshop included plenary lecturesand group breakout sessions devoted
to the discussion of issues surround-4

ing the evaluation of immunomodulators both nonclinically and clinically, as well as the interpretation
and application of that data to predict human safety. A publication isforthcoming summarizing points
discussed and conclusions reached.

Japanese Society of
Immunotoxicology - SOT
Immunotoxicology
Specialty Section
Collaboration
Submitted by Kazuichi Nakamura
In the furtherance of our growing
collaboration with the SOT IMTOX
SS, the Japanese Society of Immunotoxicology (JSIT) is happy toshare with all our most recent Newsletter. While it will be readily apparent that most of the text is in Japanese, there are actually three articles(i.e., "Miscellaneous thoughts on
immunotoxicity", "An application ofa post-hoc test followed by ANOVA
and the protocol of immunotoxicity", and "Life as a post-doc: Similarities and differences between the
US and Japan") that are written inboth Japanese and English. We will
strive to provide versions in both
Japanese and English. In the meantime, we hope that this item will at
least serve to introduce to all of you
some of the current situations andefforts of JSIT.

Note:
Please refer to the JSIT newsletterattached in it’s entirety at the end of
this newsletter.

Immunotoxicology Specialty Section

Membership Committee
ReportTotal Mem bers

400

Submitted by George DeGeorge

350
300
250

SOT Immunotoxicology Specialty
Section Membership

200
150
100
50
0
Dec-04

Jun-05

Dec-05

By Membership Category
Full
Assoc
Student

Jun-06

Dec-06

Jun-07

By Organization Category

17%

7%

1%

4%

Industry
Academia
Government
Consulting
Research
Other

10%
43%

15%

Jul 2007

68%

Total = 344
35%

Full
Assoc
Student

17%

2%
11%

Jul 2007
4%

1%

Industry
Academia
Government
Consulting
Research
Other

47%

17%

66%

Dec 2006
Total = 321

August 200735%

Dec 2006

5

Immunotoxicology Specialty Section

SOT Immunotoxicology Specialty
Section Membership (Continued)
By Membership Category
Full
Assoc
Student

By Organization Category

17%
3%

5%

Industry
Academia
Government
Consulting
Research
Other

1%

11%

46%

19%

64%

Dec 2005
Total = 349

34%

Full
Assoc
Student

Dec 2005
Industry
Academia
Government
Consulting
Research
Other

10%

2%

3%

3%

11%
21%

50%
69%

31%

Dec 2004
Total = 297
Current Year (2007)
Highest Degree
13

26

33

25

278

August 2007

Toxicology Diplomates
19%

BS/BA/BVSc/BSc
MS/MSc/MVSc/MPH/MSPH
PhD/DrPH/ScD/DSc/PharmD
MD
DVM/VMD

Note: Members with some dual degrees (MD/PhD,
PhD/DVM, etc) are counted twice in the graph.

6

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section
July 2006—June 2007

Financial Report
Submitted by
Helen V. Ratajczak
Secretary/Treasurer

Ordinary Income/Expense
IncomeAmount $Contributions
Dues - '07
Student Dues - ‘07
Grants - Food Safety
Grants - Mechanisms
Misc. Income
Registration
Interest
Total Income

Expense

200
4,365
—
—
—
—
4,337
657
9,777

Awards - Sections

1,150

Plaques
BallotExec. Meetings
Miscellaneous
Newsletter
Reception
Steno/Clerical
Symposia
Web Development

858
—
330
612
300
3,840
—
—
—

Total Expense

7,090

Excess (Deficiency) of Revenue over Expenses

2,687

Net Assets Beginning of Year

15,683

Transfers from General Fund

August 2007

Net Assets Beginning of Year after Transfers

15,683

Net Assets End of Year

18,3707

Immunotoxicology Specialty Section

Immunotoxicology Specialty Section
July 2005—June 2006

Financial Report
Submitted by

Ordinary Income/Expense

Helen V. Ratajczak
Secretary/Treasurer

IncomeIMMUNOTOXICOLOGYThe Immunotoxicology Specialty
Section is a branch of the Society of
Toxicology whose members include
scientists with training in immunology, toxicology and risk assessment. Our purpose is to promote
immunotoxicology as a disciplineby: (1) increasing our understandingof the impact that xenobiotics haveon the immune system; (2) advocating research into the mechanisms of
immunomodulation; and, (3) encouraging the development of new
methods and techniques to improverisk assessment. At the national
meeting, the Section sponsors symposia, continuing education
courses, workshops, and roundtablediscussions. Annual meetings areheld at the national meeting to discuss specialty section business andprogram topics for the following
year. The Section helps to encourage it’s pre- and postdoctoral students to participate in the scientificprogram at the Annual Meeting byawarding a prize for best presentation in the field of immunotoxicology. Student input into the Sectionis also encouraged, and facilitatedby an appointed Student Representative that attends Section Officer’s
meetings as a full voting member.

August 2007

8

Amount $Contributions
Dues - '06
Grants - Food Safety
Grants - Mechanisms
Misc. Income
Registration
Interest

500
4,005
—
—
—
4,305
747

Total Income

9,557

Expense Awards - Sections—

Plaques
BallotExec. Meetings
Miscellaneous
Newsletter
Reception
Steno/Clerical
Symposia
Web Development

727
—
641
—
200
3,699
—
1,801
—

Total Expense

7,068

Excess (Deficiency) of Revenue
over Expenses

2,489

Net Assets Beginning of Year13,193

Transfers from General Fund—Net Assets Beginning of Yearafter Transfers

13,193

Net Assets End of Year

15,683

Immunotoxicology Specialty Section

August 2007

9

Immunotoxicology Specialty Section

August 200710

Immunotoxicology Specialty Section

August 2007

11

Immunotoxicology Specialty Section

Joint Meeting:

16TH SUMMERSCHOOL IN IMMUNOTOXICOLOGYHESI-ITC IMMUNOGENICITY ROUNDTABLEICH S6 EUROPEAN DISCUSSIONSOFITEL Hotel, Lyon (France), 1-3 October 2007
Provisional program

NONCLINICAL SAFETY EVALUATION OF
BIOPHARMACEUTICALSMonday 1 October
Chairperson: J. Descotes (Lyon Poison Center, France)

10:00 Start of registration and welcome coffee
12:00 Opening lunch
13:15 Welcome to participants
13:30 TGN1412: lessons to be learnt
13:30 Part 1- A case of non-prediction ? Ch. Horwath (Archemix, USA)13:45 Part 2- ABPI/BIA recommendations regarding the MABEL approach. J. Sims (AstraZeneca, UK)
14:00 Part 3- Regulatory consequences guideline on high-risk medicinal products. Ch. Schneider (Paul Erlich Institute, Germany)
14:15 General discussion
14:45 Biopharmaceuticals: current developments and perspectives. Speaker to be confirmed
15:30 Coffee break
16:00 Adverse effects of biopharmaceuticals: from immunopharmacology to the clinic. J. Descotes
16:45 Summerschool in Immunotoxicology Annual PhD Award
17:30 Social event
20:00 Dinner

Tuesday 2 October
Chairpersons: E. Evans (Scherring-Plough, USA) & B. Molinier (Sanofi-Aventis, France)

9:00
9:30
10:00
10:30
11:45
12:30
13:45

15:45
16:15

Purpose of immunogenicity evaluation in preclinical vs clinical studies. J. Bussiere (Amgen, USA)
Overview of immunogenicity assays and regulatory aspects. R. Thorpe (National Institute for Biological Standards and Control, UK)
Practical application of immunogenicity assays. D. Finco-Kent (Pfizer, USA)
Coffee break
Risk assessment with case studies:Preclinical case studies. L. Plitnick (Merck, USA), Curtis Maier (GSK, USA)
Clinical case studies. T. Kawabata (Pfizer, USA), H. Haggerty (Bristol-Myers Squibb, USA)
Lunch
HESI-ITC Immunogenicity roundtable: risk assessment and application of the EMEA guideline on the
immunogenicity of therapeutic proteins. P. Chamberlain (MDS Pharma, France), H. Schellekens(Utrecht University, the Netherlands), Ch. Schneider, and all the speakers of the day
Coffee BreakSocial Event and Gala Dinner

August 2007

12

Immunotoxicology Specialty Section

Wednesday 3 October

Chairpersons: J-W. van der Laan (RIVM, The Netherlands) & S. Spanhaak (Johnson & Johnson

9:00
9:45
10:30
11:00
11:45
12:30
13:30
14:15
15:00
15:45
16:15
17:45

General principles and unique (molecule /class-specific) approaches in biopharmaceutical development [ICHS6]. J-W Van der Laan
Chronic toxicology studies for biopharmaceuticals. Speaker to be confirmed
Coffee break
Carcinogenicity: the need for in vitro and in vivo studies. M. Oliecsiwis (Novo-Nordisk, Denmark)Alternatives for safety assessment of biopharmaceuticals (surrogates, transgenics). Speaker to be
confirmed
Lunch
Use of non-human primates in reproduction toxicology. Speaker to be confirmed
Safety pharmacology. Speaker to be confirmed
Risk assessment of monoclonal antibodies. Speaker to be confirmed
Coffee break
Roundtable on ICH S6: where does it work and where it does not. J-W. Van der Laan, S. Spanhaak
Concluding remarks. J-W. Van der Laan, J. Descotes
Visit our web site: http://www.school-immunotoxicology.org

Recent Advancements in Immunotoxicology
Sponsored by the US Food and Drug Administration
Monday, December 3rd, 2007
9:00 AM – 3:30 PM
US FDA - White Oak Campus
Central Shared Use Building, Room 2031
Silver Spring, MD
This meeting is open to all and there is no fee for registration.
Agenda will be distributed in September.
For more information, please contact
Carmen Booker (carmen.booker@fda.hhs.gov) or
Peyton Myers (peyton.myers@fda.hhs.gov).

August 2007

13

Immunotoxicology Specialty Section

Immunotoxicology Job Announcements

BRISTOL-MYERS SQUIBB COMPANY
PHARMACEUTICAL RESEARCH INSTITUTEIMMUNOTOXICOLOGYDRUG SAFETY EVALUATIONSYRACUSE, NEW YORK
Employment Opportunity

The Immunotoxicology Department within Drug Safety Evaluation at Bristol-Myers
Squibb Co. in East Syracuse, New York is seeking an independently-thinking, highly motivated scientist with mechanistic and investigative experience in the assessment of alterations in immune status and function. Placement will be commensurate with the level of experience, but the ideal candidate will have a Ph.D. or equivalent and research backgroundin immunology and/or immunotoxicology/ immunopharmacology and a comprehensive
knowledge of animal and human biology/physiology. The candidate should also have effective written and oral communication skills and the ability to manage multiple research
activities. This person would be responsible for the scientific and toxicologic evaluation of
selected drug candidates, such as immunomodulators and protein therapeutics; design andcoordinate mechanistic and toxicology studies to support project and discovery working
groups; and develop mechanistic approaches and utilize molecular and emerging technology platforms to address toxicity issues that arise, particularly those associated with the
immune system.

Please submit letters of interest as well as academic credentials, relevant scientific publications and laboratory/research experience, and contact information for supporting references
via e-mail, fax, or US mail to:

Dr. Helen G. Haggerty and Karen Price
Department of Immunotoxicology
Drug Safety Evaluation
Pharmaceutical Research InstituteBristol-Myers Squibb Company
6000 Thompson Road, Mailstop J-4
East Syracuse, NY 13057
Fax- 315-432-2295
Email- helen.haggerty@bms.com
and karen.price@bms.com

August 2007

14

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Compiled by Haley Neff-LaFord.
ANYTIME you have a new publication to report, please sent it to the new coordinator, Haley NeffLaFord: hneff@u.washington.edu.

Asthma, Allergy, Autoimmunity & Hypersensitivity
Blossom SJ and Doss JC. Trichloroethylene alters central and peripheral immune function in autoimmuneprone MRL+/+ mice following continuous developmental and early life exposure. J Immunotoxicol 4:97-110,
2007.
Cai P, Boor PJ, Khan MF, Kaphalia BS, Ansari GAS and Konig RK. Immuno- and hepato-toxicity of dichloroacetic acid in MRL+ /+ and B6C3F1 mice. J Immunotoxicol 4:117-126, 2007.
Cauvi DM, Cauvi G and Pollard KM. Reduced expression of decay accelerating factor 1 (Daf1) in CD4+ T
cells of murine systemic autoimmune disease. Arthritis Rheum 56:1934-1944, 2007.
Corsini E and Kimber I. Factors governing susceptibility to chemical allergy. Toxicol Lett 168: 255-9, 2007.
Johnson VJ, Yucesoy B, Reynolds JS, Fluharty K, Wang W, Richardson D, Luster MI. Inhalation of toluene
diisocyanate vapor induces allergic rhinitis in mice. J Immunol 179:1864-71, 2007.
Kimber I, Agius R, Basketter DA, Corsini E, Cullinan P, Dearman RJ, Gimenz-Arnau E, Greenwell L, Hartung T, Kuper F, Maestrelli P, Roggen E and Rovida C. Chemical respiratory allergy: opportunities for hazard
identification and characterization. Altern Lab Anim 35:243-265, 2007.
Larsen ST, Hansen JS, Hansen EW, Clausen PA and Nielsen GD. Airway inflammation and adjuvant effectafter repeated airborne exposures to di-(2-ethylhexyl)phthalate and ovalbumin in BALB/c mice. Toxicology
235:119-129, 2007.
Mahajan SG, Mali RG and Mehta AA. Protective effect of ethanolic extract of seeds of Moringa oleifera Lam.
against inflammation associated with development of arthritis in rats. J Immunotoxicol 4:39-47, 2007.
Regal JF, Regal RR, Meehan JL, Mohrman ME. Primary Prevention of Asthma: Age and Sex Influence Sensitivity to Allergen-induced Airway Inflammation and Contribute to Asthma Heterogeneity in Guinea Pigs. Int
Arch Allergy Immunol 141:241-256, 2006.
Ueda H, Ebino K, Kosaka T, Nakashima N, Chiba Y, Harada T and Teramoto S. Assessment of airway sensitization potential of inhaled trimellitic anhydride by monitoring the elicitation phase in a mouse model. J Immunotoxicol 4:155-164, 2007.

August 200715

Immunotoxicology Specialty SectionEffects: Compounds
Antonini JM and Roberts JR. Chromium in stainless steel welding fume suppresses lung defense response
against bacterial infection in rats. J Immunotoxicol 4:85-96, 2007.
Corsini E, Codecà I, Mangiaratti S, Birindelli S, Minoia C, Turci R, Viviani B, Facchi A, Vitelli N, Lucchi L,
Galli CL, Marinovich M and Colosio C. Immunomodulatory effects of the herbicide propanil on cytokine production in humans: in vivo and in vitro exposure. Toxicol Appl Pharmacol 222: 202-210, 2007.
Mahajan SG, Mali RG and Mehta AA. Effect of Moringa oleifera Lam. Seed extract on toluene diisocyanateinduced immune-mediate inflammatory responses in rats. J Immunotoxicol 4:143-154, 2007.
Oyama Y, Matsui H, Morimoto M, Sakanasi Y, Nishimura Y, Ishida S and Okano Y. Synergic cytotoxic action induced by simultaneous application of zinc and clotrimazole in rat thymocytes. Toxicol Lett 171:138145, 2007.
Sivertson KL, Seeds MC, Long DL, Peachman KK and Bass DA. The differential effect of dexamethasone on
granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils. Cell Immunol
246:34-45, 2007.
Sun NN, Wong SS, Nardi C, Ostroff D, Witten ML and Lantz RC. In vitro pro-inflammatory regulatory roleof substance P in alveolar macrophages and type II pneumocytes after JP-8 exposure. J Immunotoxicol 4:6167, 2007.
Zhou X, Yang N, Lu L, Ding Q, Jiao Z, Zhou Y and Chou KY. Up-regulation of IL-10 expression in dendritic
cells is involved in Trichosanthin-induced immunosuppression. Immunol Lett 110:74-81, 2007.
General Immunotoxicology
Anderson SE, Meade BJ, Butterworth LF and Munson AE. The humoral immune response of mice exposed tomanual metal arc stainless steel-welding fumes. J Immunotoxicol 4:15-23, 2007.
Cao Q, Zhang S, Dong C and Song W. Pulmonary responses to fine particles: differences between the spontaneously hypertensive rats and Wistar Kyoto rats. Toxicol Lett 171:126-137, 2007.
Cohen MD, Sisco M, Prophete C, Chen LC, Zelikoff JT, Ghio AJ, Stonehuerner JD, Smee JJ, Holder AA andCrans DC. Pulmonary immunotoxic potentials of metals are governed by select physicochemical properties:
vanadium agents. J Immunotoxicol 4:49-60, 2007.
Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S and Kaveri SV.
Immune response against therapeutic factor VIII in hemophilia A patients—a survey of probable risk factors.
Immunol Lett 110:23-28, 2007.

August 2007

16

Immunotoxicology Specialty Section

Denkinger CM, Denkinger MD and Forsthuber TG. Pertussis toxin-induced cytokine differentiation andclonal expansion of T cells is mediated predominantly via costimulation. Cell Immunol 246:46-54, 2007.
Fulco TO, Lopes UG, Sarno EN, Sampaio EP and Saliba AM. The proteasome function isrequired for Mycobacterium leprae-induced apoptosis and cytokine secretion. Immunol Lett 110:82-85, 2007.
Kin N and Sanders VM. CD86 regulates IgG1 production via a CD19-dependent mechanism. J Immunol
179:1516-1523, 2007.
Martin PL, Oneda S and Tracy G. Effects of an anti-TNFa monoclonal antibody, administered throughout
pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 58:138–
149a, 2007.
Mei Y, Wang Y and Xu L. Suppression of immune-mediated liver injury after vaccination with attenuatedpathogenic cells. Immunol Lett 110:29-35, 2007.
Neff-LaFord H, Teske S, Bushnell TP and Lawrence BP. Aryl hydrocarbon receptor activation during influenza virus infection unveils a novel pathway of IFNg production by phagocytic cells. J Immunol 179: 247255.
Models & Methods
Bugelski PJ and Kim C. T-dependent antigen response (TDAR) tests: meta-analysis of results generated
across multiple laboratories. J Immunotoxicol 4:111-116, 2007.
Carfi' M, Gennari A, Malerba I, Corsini E, Pallardy M, Pieters R, Van Loveren H, Vohr HW, Hartung T,
Gribaldo L. In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 229:11-22, 2007.
Haggerty HG. Immunotoxicity testing in non-rodent species. J Immunotoxicol 4:127-132, 2007.
Herzyk DJ and Holsapple MJ. Immunotoxicity evaluation by immune function tests: focus on the Tdependent antibody response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the
SOT. March 5-9, 2006 San Diego, CA]. J Immunotoxicol 4:133-138, 2007.
Koganei A, Tsuchiya T, Samura K and Nishikibe M. Use of whole sheep red blood cells in ELISA to assess
immunosuppression in vivo. J Immunotoxicol 4:77-82, 2007.
Ladics GS. Primary immune response to sheep red blood cels (SRBC) as the conventional T cell-depende antibody response (TDAR) test. J Immunotoxicol 4:139-142, 2007.
Pruett S, Hebert P, Lapointe JM, Reagan W, Lawton M and Kawabata TT. Characterization of the action of
drug-induced stress responses on the immune system: evaluation of biomarkers for drug-induced stress in rats.
J Immunotoxicol 4:25-38, 2007.

August 200717

Immunotoxicology Specialty Section

Regal JF, Regal RR, Meehan JL, Duan M, Mohrman ME. Contributions of age and sex to heterogeneity ofsymptoms and effectiveness of secondary prevention strategies in asthma as modeled in the guinea pig. J Immunotoxicol 4:1-13, 2007.
White KL Jr, Sheth CM and Peachee VL. Comparison of primary immune responses to SRBC and KLH inrodents. J Immunotoxicol 4:165, 2007.
Reviews and Book Chapters:
Dearman RJ and Kimber I. The use of cytokines in the identification and characterization of chemical allergens. In: Methods in Pharmacology and Toxicology: Cytokines in Human Health: Immunotoxicology, Pathology and Therapeutic Applications. Eds: RV House and J Descotes, Humana Press, Totowa, pp 67-81, 2007.
Fisher IB, Kin N, McAlees JW and Sanders VM. Regulation of Adaptive Immunity by the Neurotransmitter
Norepinephrine. Curr Immunol Rev 2:361-370, 2006.
Fujii H. Mechanisms of signal transduction from receptors of type I and type II cytokines. J Immunotoxicol
4:69-76, 2007.
Lawrence BP. Environmental toxins as modulators of antiviral immune responses. Viral Immunol 20:231242, 2007.
Regal JF, Greene AL and Regal RR. Mechanisms of occupational asthma: not all allergens are equal. Environmental Health and Preventive Medicine 12:161-167, 2007.
Letter to the editor:
Pollard KM and Hultman P. Skin-lightening creams are a possible exposure risk for systemic lupus erythematosus. Arthritis Rheum 56:1721, 2007.

August 2007

18

Immunotoxicology Specialty Section